You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微泰醫療-B(02235.HK)中期收入為7180萬元 同比增長20.9%
格隆匯 08-29 23:10

格隆匯8月29日丨微泰醫療-B(02235.HK)公吿,截至2022年6月30日止六個月,公司實現收入為人民幣7180萬元,同比增長20.9%。其中主要增長來自於(i)AiDEXG7持續葡萄糖監測系統的商業化;(ii)貼敷式胰島素泵的國內市場份額增長;及(iii)血糖監測系統產品收入的穩定增長。公司的產品組合,將持續受益於中國和全球日益增長的糖尿病治療、監測和管理的用户需求。相較去年同期,公司的毛利略有增長,毛利率有所下降,但相較2021年下半年毛利率環比有所增長,主要原因是(i)產品商業化收入持續增長;(ii)第二季度上海及周邊地區的疫情封控措施對於公司的供應鏈及生產成本,造成短期不利影響。隨着2022年第二季度末疫情風控逐步解除,供應鏈和生產已恢復正常。母公司擁有人應占虧損794萬元,上年同期虧損1905.6萬元;每股虧損0.02元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account